Karim Benabdellah is a researcher specializing in gene therapy, genomic editing, and immuno-oncology. He received his Ph.D.  degree in Biological from the University of Granada (UGR). After completing his doctoral thesis, he pursued two national postdoctoral research positions at the López-Neyra Institute (CSIC) and the Estación Experimental del Zaidín (CSIC), securing a competitive JAE-CSIC postdoctoral contract (2006–2009). In 2009, he expanded his international experience as a visiting scientist at the University of Torino. In 2010, he joined the Andalusian Health Council, initially contributing to the Andalusian Stem Cell Bank (2010–2018). Later, he secured a Nicolás Monardes contract, and in 2023, he was promoted to Principal Investigator Level II after obtaining R3 accreditation from Spain’s Ministry of Science, Innovation, and Universities. He actively participates in teaching at UGR’s genetic and translational medicine doctoral programs and serves as a member of the academic committee for the UGR-Biomedicine Ph.D. program. At Genyo, he lead an independent research group focused on advancing oncological immunotherapy through CAR-T technology and genomic editing tools. His work has been recognized with the R3 certification as an established researcher within Spain’s Science, Technology, and Innovation System. In 2021, he was awarded first prize in the Technological Innovation category by ROCHE and, in 2023, he won the XI University Entrepreneurship Contest (UGR).